证券代码：300452 证券简称：山河药辅 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2024 年度） 债券受托管理人 二〇二五年六月 （安徽省合肥市梅山路 18 号） 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称《管理办法》）、 《安 徽山河药用辅料股份有限公司向不特定对象发行可转换公司债券之受托管理协 议》（以下简称《受托管理协议》）、 《安徽山河药用辅料股份有限公司向不特定对 象发行可转换公司债券并在创业板上市募集说明书》（以下简称《募集说明书》） 《安徽山河药用辅料股份有限公司 2024 年年度报告》等相关公开信息披露文件、 第三方中介机构出具的专业意见等，由本期债券受托管理人国元证券股份有限公 司（以下简称"国元证券"）编制。国元证券对本报告中所包含的从上述文件中 引述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性 和完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为国元证券所 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-029 债券代码：123199 债券简称：山河转债 转股起止时间：2023 年 12 月 18 日至 2029 年 6 月 11 日 暂停转股时间：2025 年 6 月 13 日至 2024 年度权益分派股权 登记日 恢复转股时间：2024 年度权益分派股权登记日后的第一个交易 日 安徽山河药用辅料股份有限公司（以下简称"公司")于 2025 年 5 月 13 日召开的 2024 年度股东大会审议通过了《公司 2024 年度 利润分配预案》，公司将根据相关规定实施 2024 年度权益分派。根 据《安徽山河药用辅料股份有限公司公开发行可转换公司债券募集说 明书》第二节中"转股价格的调整方式及计算公式"相关条款的规定， 自 2025 年 6 月 13 日至 2024 年度权益分派股权登记日止，公司 可转换公司债券"山河转债"将暂停转股。本次权益分派股权登记日 后的第一个交易日起恢复转股。 安徽山河药用辅料股份有限公司 关于实施权益分派期间"山河转债"暂停转股的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特 ...

Group 1 - The company, Anhui Shanhe Pharmaceutical Auxiliary Materials Co., Ltd., is issuing convertible bonds named "Shanhe Convertible Bonds" with a face value of 1,000.00 yuan and an annual interest of 5.00 yuan (including tax) [1][2] - The interest payment method for the convertible bonds is annual, with the first interest payment starting from the issuance date [1][2] - The interest calculation formula is provided, where the annual interest (I) is calculated as I = B × i, with B being the total face value held and i being the annual coupon rate [1] Group 2 - The interest payment date is set for each year on the anniversary of the bond issuance, with provisions for adjustments if the date falls on a holiday [2] - The bondholders must be registered with the China Securities Depository and Clearing Corporation Limited by the specified date to receive interest payments [4] - The company has appointed the China Securities Depository and Clearing Corporation Limited to handle the interest payments [4] Group 3 - Tax obligations for interest income are specified, with a 20% withholding tax for individual bondholders, while qualified foreign institutional investors (QFII and RQFII) are exempt from corporate income tax and value-added tax [3][5] - The company does not withhold taxes for other bondholders, who are responsible for their own tax payments [3][5] - The announcement includes contact information for inquiries regarding the bond issuance [5]

证券代码：300452 证券简称：山河药辅 公告编号：2025-028 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 可转换公司债券付息公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1."山河转债"将于 2025 年 6 月 12 日按面值支付第二年利息，每 10 张"山 河转债"（面值 1,000.00 元）利息为 5.00 元（含税）。 2. 债权登记日：2025 年 6 月 11 日。 3. 除息日：2025 年 6 月 12 日。 4. 付息日：2025 年 6 月 12 日。 5."山河转债"票面利率：第一年 0.2%、第二年 0.5%、第三年 1.0%、第四 年 1.5%、第五年 2.0%、第六年 3.0%。 6."山河转债"本次付息的债权登记日为 2025 年 6 月 11 日，凡在 2025 年 6 月 11 日（含）前买入并持有本期债券的投资者享有本次派发的利息；2025 年 6 月 11 日卖出本期债券的投资者不享有本次派发的利息。 7.下一付息期起息日：2025 年 6 月 12 日，下一年度利率：1.0 ...

安徽山河药用辅料股份有限公司 2025 年度跟踪评级报告 编号：信评委函字[2025]跟踪 0336 号 安徽山河药用辅料股份有限公司 2025 年度跟踪评级报告 声 明 中诚信国际信用评级有限责任公司 2025 年 5 月 30 日 2 本次评级为委托评级，中诚信国际及其评估人员与评级委托方、评级对象不存在任何其他影响本次评级行为独立、 客观、公正的关联关系。 本次评级依据评级对象提供或已经正式对外公布的信息，以及其他根据监管规定收集的信息，中诚信国际按照相关 性、及时性、可靠性的原则对评级信息进行审慎分析，但中诚信国际对于相关信息的合法性、真实性、完整性、准 确性不作任何保证。 中诚信国际及项目人员履行了尽职调查和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 评级报告的评级结论是中诚信国际依据合理的内部信用评级标准和方法、评级程序做出的独立判断，未受评级委托 方、评级对象和其他第三方的干预和影响。 本评级报告对评级对象信用状况的任何表述和判断仅作为相关决策参考之用，并不意味着中诚信国际实质性建议任 何使用人据此报告采取投资、借贷等交易行为，也不能作为任何人购买、出售或持有相关金融产品的依 ...

证券代码：300452 证券简称：山河药辅 公告编号：2025-026 安徽山河药用辅料股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担个别及连带责任。 2．网络投票时间：通过深圳证券交易所交易系统进行网络投票 的具体时间为：2025年5月13日上午9:15—9：25，9：30—11:30 和 下午13:00—15:00； 通过互联网投票系统投票的具体时间为：2025 年5月13日上午 9:15至2025年5月13日下午 15:00期间的任意时间。 3．股权登记日：2025年5月6日。 4．现场会议召开地点：安徽省淮南市经济技术开发区河滨路2 号公司三楼会议室 5．会议召集人：公司董事会 6．会议主持人：董事长尹正龙先生 一、重要提示 1、本次会议召开期间没有增加、否决或变更提案； 2、本次股东大会以现场投票结合网络投票方式进行。 二、会议召开和出席情况 1．现场会议召开时间：2025年5月13日（星期二）下午2:30 2、审议通过《公司2024年度监事会工作报告》。 7．出席本次股东大会的 ...

天禾律师事务所 法律意见书 安徽天禾律师事务所 关于安徽山河药用辅料股份有限公司 2024年年度股东大会的法律意见书 天律意2025第1094号 致：安徽山河药用辅料股份有限公司 券交易所交易系统进行网络投票的时间为：2025 年 5 月 13 日 9:15－9:25，9:30 －11:30，13:00－15:00；通过深圳证券交易所互联网投票系统投票的时间为 2025 年 5 月 13 日 9:15 至 15:00 期间的任意时间。 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和国 证券法》（下称"《证券法》"）、中国证券监督管理委员会《上市公司股东会规 则》（下称"《股东会规则》"）以及《安徽山河药用辅料股份有限公司章程》（下 称"《公司章程》"）的有关规定，安徽天禾律师事务所接受安徽山河药用辅料股 份有限公司（下称"公司"）的委托，指派王小东、杨帆律师（下称"天禾律师"） 出席公司 2024 年年度股东大会（下称"本次股东大会"），并对本次股东大会相 关事项进行见证，出具法律意见。 本法律意见书是天禾律师根据对本次股东大会事实的了解及对我国现行法 律、法规和规范性文件的理解而出具的。 ...

Group 1: Company Overview - Recently, a well-known private equity firm, Xiangju Capital, conducted research on a listed company, Shanhe Pharmaceutical Auxiliary [1] - Shanhe Pharmaceutical Auxiliary expects a 22% growth in sales revenue for cellulose products in 2024, with a slight decline in overall prices [1] - The company anticipates stable prices in 2025 and strong demand for its products [1] Group 2: Financial Performance - Last year's gross margin slightly decreased, but there is potential for improvement this year [1] - The capacity utilization rate for four main products in the fundraising projects is between 60% and 70% [1] - The company expects significant growth in the sales of hard fumaric acid sodium in 2024, with over 100 domestic customers already using the product [1] Group 3: Market Dynamics - The auxiliary materials industry has vast potential, with many categories and significant room for import substitution, accelerated by the China-US trade war [1] - The new drug production quality management regulations will be implemented on January 1, 2026, which is expected to accelerate industry consolidation, benefiting leading companies [1] - The demand for plant capsules is strong, with good order prospects in the next six months, and there is potential for domestic gelatin capsules to be replaced [1] Group 4: International Business - The increase in tariffs by the US has not yet affected exports, as the export volume to the US is relatively small, and some products fall within the tariff exemption range [1] - Overseas business is expected to maintain rapid growth, although the gross margin is slightly lower due to fewer differentiated products being sold abroad [1]

Group 1: Financial Performance - The sales revenue of cellulose products in 2024 reached 474 million CNY, representing a year-on-year growth of 22% [2] - The overall gross margin slightly decreased last year, but the decline was minimal, influenced by market structure adjustments [2] - The utilization rate of new production capacity for four main products is currently between 60%-70% [2] Group 2: Market Demand and Trends - The demand for hydroxypropyl methylcellulose is currently strong, with no signs of decline, particularly in the plant capsule and pharmaceutical adhesive markets [5][6] - The market for excipients is broad, with over 1,000 types used internationally and around 500 types in China, while the company currently produces only over 40 types [3] - The import substitution space remains significant, accelerated by the US-China trade war [3] Group 3: Regulatory Impact - The new drug production quality management standards will be implemented on January 1, 2026, which includes the management of pharmaceutical excipients [4] - The company has conducted a comprehensive self-inspection to meet the new management requirements [4] Group 4: International Business and Export - The company expects to maintain high growth in overseas markets, with plans to expand the overseas management and sales team in 2025 [8] - The export volume to the US is relatively small, not exceeding 10 million CNY, and is currently unaffected by increased tariffs [7] - The gross margin for overseas sales is slightly lower due to fewer product categories compared to domestic offerings [8]

Financial Performance - The company reported a decline in performance for 2024, primarily due to goodwill impairment and convertible bond interest expenses, which significantly impacted operating results [2][21]. - Excluding these factors, the company maintained stable profit growth, despite a challenging market environment [21]. - The pharmaceutical industry faced a consumption slowdown, with a reported revenue growth rate of 3.0% and a profit decline of 8.3% for the drug auxiliary materials and packaging industry in 2024 [10]. Market Position and Strategy - The company holds a leading position in the solid preparation drug auxiliary materials sector, with 47 products and 27 products passing related reviews [10]. - The company has successfully helped clients achieve over 170 projects for domestic substitution of imported auxiliary materials, enhancing supply chain stability and reducing costs [29]. - The domestic market for drug auxiliary materials still relies heavily on imports, indicating significant potential for growth in domestic production [29]. Product Development and Innovation - The company is focusing on high-end drug auxiliary materials and new product development, particularly in areas like injectable materials and transdermal patches [18]. - There is an emphasis on expanding applications of existing products in new sectors such as medical beauty, daily chemicals, and animal protection [18]. - The company is actively exploring opportunities for capital cooperation to enhance its market position and profitability [20]. Investor Relations and Market Confidence - The company has implemented measures for market value management, including share buybacks and increased cash dividends, with a proposed cash dividend of 3.0 RMB per 10 shares for 2024, totaling approximately 69.79 million RMB [22]. - The company is committed to maintaining effective communication with investors and addressing concerns regarding stock price fluctuations influenced by macroeconomic factors [13][21]. - The management remains optimistic about future growth opportunities, particularly in response to increasing demand for domestic substitutes and new product lines [20][29].